Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6974635 | 0.97 | TSHR (0.55) | TSHRGAAESR1ALOX15HSD17B10 | |
| SCHEMBL6982149 | 0.97 | TSHR (0.57) | TSHRGAAESR1ALOX15HSD17B10 | |
| SCHEMBL6969321 | 0.90 | TSHR (0.57) | TSHRGAAESR1ALOX15HSD17B10 | |
| SCHEMBL10654605 | 0.85 | TSHR (0.60) | TSHRGAAESR1ALOX15HSD17B10 | |
| SCHEMBL6978785 | 0.84 | TSHR (0.51) | TSHRGAAKMT2AQPCTMAPK1 | |
| SCHEMBL6978069 | 0.82 | TSHR (0.59) | TSHRGAAESR1ALOX15HSD17B10 | |
| SCHEMBL6977516 | 0.82 | PGR (0.58) | TSHRGAAESR1ALOX15HSD17B10 | |
| SCHEMBL6979322 | 0.81 | TSHR (0.53) | TSHRGAAESR1ALOX15HSD17B10 | |
| SCHEMBL6967571 | 0.81 | TSHR (0.50) | TSHRGAAKMT2AQPCTMAPK1 | |
| SCHEMBL6980189 | 0.81 | TSHR (0.52) | TSHRGAAESR1ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | TSHR 3090/4885GAA 638/4885ESR1 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.